Syd Uni sports clinic
22-06-2006, 01:07 PM
This item of small print from a recent paper is a ripper. The paper itself is a fairly standard RCT study showing higher rates of GI complication in traditional NSAIDs compared to Celebrex (although lower rates of cardiac events, which the authors don't highlight as much). The amazing feature of the paper is the conflict of interest statement, reproduced below. Pfizer appeared to have conducted the study itself and the authors attached their names to it after the data was collected! The numbers of grants and payments from pharmaceutical companies (particularly Pfizer/Pharmacia but the full gamut really) is amazing. How this doesn't taint the authors is beyond me, although at least we get the statements in the journal nowadays so the potential bias is declared.
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study
Gurkirpal Singh MDa, , , John G. Fort MDb, Jay L. Goldstein MDc, Roger A. Levy MDd, Patrick S. Hanrahan MDe, Alfonso E. Bello MDc, Lilia Andrade-Ortega MDf, Carl Wallemarkb, Naurang M. Agrawal MDg, Glenn M. Eisen MDh, William F. Stenson MDi, George Triadafilopoulos MDa and SUCCESS-I Investigators
The American Journal of Medicine
Volume 119, Issue 3 , March 2006, Pages 255-266
Conflict of interest statement:
This study was supported by a grant from Pharmacia Corporation and Pfizer, Inc. The study design as well as data analysis and interpretation were performed by the study design committee, of which the sponsor was a member. The study sponsors were responsible for data collection and management, in collaboration with the authors. Two independent Gastrointestinal Events adjudication committees performed the data analysis and interpretation of gastrointestinal events. The authors had full access to all the data and had final responsibility for data analysis, interpretation, manuscript preparation and the decision to submit for publication. Conflict of Interest Statement: Gurkirpal Singh received research support from Searle, Pharmacia, Pfizer, Merck, Boehringer Ingelheim, TAP Pharmaceuticals, Wyeth, Altana, Glaxo Smith Kline, Novartis, and Centocor; consultancies, travel grants, speakers bureau from Searle, Pharmacia, Pfizer, Merck and Boehringer Ingelheim. John G. Fort and Carl Wallmark were employees of Pharmacia/Pfizer and own stock in Pfizer, Inc. Jay L. Goldstein: consultancies, honoraria, travel grants, travel expenses, speakers bureau, and research grants from Searle, Pharmacia, Pfizer, TAP Pharmaceuticals, and Astra-Zeneca. Roger A. Levy: Investigator and Speakers bureau (Pfizer, Aventis, Wyeth and Schering-Plough); Advisory board (Pfizer and Novartis). Patrick S. Hanrahan: travel grants from Pfizer. Alfonso E. Bello: former employee of Pharmacia/Pfizer. Lilia Andrade-Ortega: Advisory board (Pfizer); travel grants (Schering Plough). Naurang M. Agrawal: honoraria (Pharmacia and Pfizer); advisory board (Pfizer). Glenn M. Eisen: consultancies and honoraria (Pfizer). William F. Stenson: consultancies (Pharmacia and Pfizer). George Triadafilopoulos: research support from Pfizer, Astra-Zeneca and TAP Pharmaceuticals; consultant to Pfizer, Merck, Boerhinger-Ingelheim, Astra-Zeneca, TAP Pharmaceuticals, Janssen and Wyeth; honoraria and travel support for lectures and meetings from Pfizer, Merck, Boerhinger-Ingelheim, Astra-Zeneca, TAP Pharmaceuticals, Janssen and Wyeth.
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study
Gurkirpal Singh MDa, , , John G. Fort MDb, Jay L. Goldstein MDc, Roger A. Levy MDd, Patrick S. Hanrahan MDe, Alfonso E. Bello MDc, Lilia Andrade-Ortega MDf, Carl Wallemarkb, Naurang M. Agrawal MDg, Glenn M. Eisen MDh, William F. Stenson MDi, George Triadafilopoulos MDa and SUCCESS-I Investigators
The American Journal of Medicine
Volume 119, Issue 3 , March 2006, Pages 255-266
Conflict of interest statement:
This study was supported by a grant from Pharmacia Corporation and Pfizer, Inc. The study design as well as data analysis and interpretation were performed by the study design committee, of which the sponsor was a member. The study sponsors were responsible for data collection and management, in collaboration with the authors. Two independent Gastrointestinal Events adjudication committees performed the data analysis and interpretation of gastrointestinal events. The authors had full access to all the data and had final responsibility for data analysis, interpretation, manuscript preparation and the decision to submit for publication. Conflict of Interest Statement: Gurkirpal Singh received research support from Searle, Pharmacia, Pfizer, Merck, Boehringer Ingelheim, TAP Pharmaceuticals, Wyeth, Altana, Glaxo Smith Kline, Novartis, and Centocor; consultancies, travel grants, speakers bureau from Searle, Pharmacia, Pfizer, Merck and Boehringer Ingelheim. John G. Fort and Carl Wallmark were employees of Pharmacia/Pfizer and own stock in Pfizer, Inc. Jay L. Goldstein: consultancies, honoraria, travel grants, travel expenses, speakers bureau, and research grants from Searle, Pharmacia, Pfizer, TAP Pharmaceuticals, and Astra-Zeneca. Roger A. Levy: Investigator and Speakers bureau (Pfizer, Aventis, Wyeth and Schering-Plough); Advisory board (Pfizer and Novartis). Patrick S. Hanrahan: travel grants from Pfizer. Alfonso E. Bello: former employee of Pharmacia/Pfizer. Lilia Andrade-Ortega: Advisory board (Pfizer); travel grants (Schering Plough). Naurang M. Agrawal: honoraria (Pharmacia and Pfizer); advisory board (Pfizer). Glenn M. Eisen: consultancies and honoraria (Pfizer). William F. Stenson: consultancies (Pharmacia and Pfizer). George Triadafilopoulos: research support from Pfizer, Astra-Zeneca and TAP Pharmaceuticals; consultant to Pfizer, Merck, Boerhinger-Ingelheim, Astra-Zeneca, TAP Pharmaceuticals, Janssen and Wyeth; honoraria and travel support for lectures and meetings from Pfizer, Merck, Boerhinger-Ingelheim, Astra-Zeneca, TAP Pharmaceuticals, Janssen and Wyeth.